With the New Year came another lawsuit filed over Benicar (generic “olmersartan”). As the 2012 Mayo Clinic’s case study linking Benicar to severe sprue-like enteropathy continues to be discussed, patients are coming forward to report the negative side effects they have suffered from taking the drug. A lawsuit filed in the Northern District of California in January 2015 alleges that the makers of Benicar did not properly warn patients about the risks associated with the drug. See Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in US District Court, Northern District of California.
Plaintiffs are specifically concerned about the link between Benicar and sprue-like enteropathy. According to the complaint, two plaintiffs, Louis Verduzco and Michael Ewald, developed personal injuries including “sprue-like enteropathy, villous atrophy, lymphocytic colitis, microscopic colitis, collagenous colitis, and/or intestinal malabsorption.” Symptoms of sprue-like enteropathy include severe, chronic diarrhea, intestinal problems and substantial weight loss. These symptoms mimic that of Celiac disease, but they are not the same thing.
For these plaintiffs, exposure to the drug resulted in chronic diarrhea, rapid weight loss, dehydration and/or acute renal failure. The plaintiffs allege they had to be hospitalized for their conditions and now require ongoing medical monitoring. They also allege that they were unaware of any adverse side effects associated with Benicar, and that the maker of the drug, Daiichi Sankyo, did not properly test it to prove that it was actually effective for treating hypertension.